Vertex Rallies Into Results, Then Slips as Analysts Raise Targets

VRTX reported Q3 earnings on November 2 and promptly fell 5%, a drop that left the stock at $530.76 despite a week-over-week gain of roughly 1.9%, and triggered a wave of analyst target increases that now sit well above where the shares are trading.

The options market had flagged the tension before the print. The put/call ratio climbed to 1.10 by November 3, nearly 2.7 standard deviations above its 20-day average of 0.94. That is the most defensive reading in several months and close to the 52-week high of 1.27. The shift was rapid: the ratio spent most of October below 0.98 before moving sharply higher in the final two sessions of last week. Options traders were right to hedge. The stock fell 5% on the day results landed, in line with the degree of caution the positioning implied.

Short sellers are not the story here. Short interest ticked up 4.5% over the past week to 1.75% of the free float, reversing part of the decline reported in the earnings preview published October 30. Even after the reversal, the absolute level remains low. Borrowing costs have risen 80% over the past week to 0.55%, which looks striking in percentage terms but translates to an annualised rate of under 1%. Availability is effectively uncapped, with over 251 million shares available to borrow against roughly 4.4 million shares short. There is no squeeze pressure and no structural friction for anyone who wants to put on or take off a position. The post-earnings dip has not sparked a rush to press the short case.

Where the action is concentrated is on the analyst desks. The Street has responded to the Q3 results with almost universal target increases, all within the past 48 hours. Goldman Sachs made the boldest move, raising its target to $725 from $654 while holding its Buy rating. Wells Fargo lifted to $650 from $550 and Scotiabank moved to $660 from $558, both maintaining positive ratings. Barclays raised to $626 and JP Morgan to $570. The lone outlier was Morgan Stanley, which trimmed its target by $5 to $660, a marginal reduction that keeps it firmly in the Overweight camp. The mean price target now stands at $577, roughly 9% above the current share price. The consensus direction is clear: firms that reviewed the numbers came away more constructive on the pipeline, not less. The bear case centres on Trikafta revenue missing consensus modestly and pipeline execution risk in programs like povetacicept and inaxaplin. The bull case rests on the CF franchise's durability and a revenue path the company has described as reaching toward $28 billion by 2035.

The alt data adds a layer of context on the demand side of the CF business. Medicaid prescriptions tracked by the Centers for Medicare and Medicaid Services rose 59% in Q1 2026 compared with the same quarter a year earlier, reaching 25,471 prescriptions. That marks a fourth consecutive quarter of year-on-year growth. The dataset has not been measured as a leading indicator of Vertex's reported financials, so it cannot be read as a forecast of the revenue line. It does, however, confirm that government-payer utilisation of the CF drug portfolio is still expanding at a substantial pace. The buyback picture tells a different story: remaining authorisation has fallen for three consecutive quarters and is down 43% year-on-year at $2.6 billion, suggesting the company is deploying capital elsewhere or at a slower rate than before. The next earnings event is not until February 8, 2027, leaving 96 days for the analyst target upgrades and the options reset to work through the market.

The gap between where the shares closed and where the analyst community is now pointing is the clearest tension to track: the stock fell on results that prompted most of its coverage to raise estimates, and borrow conditions give short sellers every opportunity to press further if they choose.